The US Food and Drug Administration has scheduled a public meeting to discuss its forthcoming pilot programme under which pharmaceutical companies will be able to check in advance whether their proposed invented trade names are likely to be acceptable to the agency1-3. The FDA hopes the programme will help reduce the number of medication errors that result from proprietary names that look or sound like the names of other medical products.
The initiative is one of the projects imposed on the FDA by the Prescription Drug User Fee Act (PDUFA IV)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?